<DOC>
	<DOCNO>NCT01437449</DOCNO>
	<brief_summary>Docetaxel cetuximab FDA approve treatment squamous cell carcinoma head neck . Cisplatin carboplatin , FDA approve Squamous Cell Carcinoma Head Neck ( SCCHN ) , use standard care patient SCCHN combination drug . This study determine weekly cisplatin docetaxel , combination cetuximab , effective palliative treatment patient squamous cell carcinoma head neck . These drug give intravenously weekly , repeat 3 every 4 week evidence disease progression unacceptable adverse event .</brief_summary>
	<brief_title>Weekly Docetaxel , Cisplatin , Cetuximab ( TPC ) Palliative Treatment Patients With Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Squamous cell carcinoma head neck site , include pharynx , larynx , oral cavity , skin paranasal sinus site . Patients SCC unknown primary present neck clinically compatible head neck mucosal primary site eligible . Patients receive prior chemoradiation , radiation , and/ surgery potentially curative set eligible long 3 month elapse since end potentially curative treatment end . Patients must great 16 year old . ECOG Performance Status &lt; 3 enrollment require . Laboratory value requirement enrollment : Absolute neutrophil count &gt; 1500/mm3 Platelet count &gt; 100K/mm3 Hemoglobin &gt; 8 g/dL AST ALT &lt; 2.5 x ULN unless liver metastasis document . In latter case , AST ALT &lt; 5 x ULN require . Total Bilirubin &lt; 1.5 x ULN unless patient Gilbert 's syndrome , case T. Bilirubin &lt; 2.5 x ULN require Serum Creatinine &lt; 1.5 mg/dL OR estimate creatinine clearance 24 hour urine collection &gt; 50 ml/min Clinical requirement enrollment : Peripheral neuropathy &lt; grade 2 Hearing loss best ear &lt; grade 2 per Chang criterion audiogram perform . *24 Formal audiology require patient clinical evidence hearing loss baseline . Ability understand willingness sign write informed consent document . No prior palliative chemotherapy Patients active infection include HIV eligible . HIV positive patient HAART undetectable blood HIV level eligible . Patients history serological evidence exposure Hepatitis B without active infection eligible study . Patients prior grade 3 allergic infusion reaction docetaxel , cisplatin cetuximab eligible . A history well tolerate infusion reaction NOT exclusion . Pregnant woman and/or nurse patient exclude study potential harm fetus nursing infant . Because primary endpoint study response rate survival , patient history malignancy treat curatively great one year prior enrollment without evidence relapse time enrollment eligible . Patients brain metastasis eligible CNS image evidence CNS progression least 30 day follow definitive CNS treatment ( resection radiation ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Quality Life</keyword>
</DOC>